معرفی
Professor Janne Lehtiö leads the Cancer Proteogenomics Group at the Department of Oncology-Pathology, Karolinska Institutet. His research focuses on integrating genomics and proteomics to understand cancer mechanisms in leukaemias, lung cancer, and breast cancer, with clinical translation via decision support systems.
- Education:
- MSc in Biochemistry, University of Helsinki
- PhD in Biotechnology, Royal Institute of Technology (KTH)
- Postdoctoral training in cancer research, KI
Research interests: Lehtiö’s group develops cutting-edge mass spectrometry methods (e.g., HiRIEF, SubCellBarCode) and bioinformatics pipelines to map cancer proteogenomics, identify immunotherapy targets, and refine treatment selection through proteome-wide analysis.
Article trends: His team’s publications emphasize spatial proteomics, precision oncology, and clinical decision systems, with methodological innovations like SubCellBarCode enabling protein localization studies and DEqMS improving statistical rigor in proteomics.
Scientific recognition:
- Board of Directors, Cancer Core Europe (2023)
- Scientific Director, Science for Life Laboratory (2018-2023)
- Swedish Mass Spectrometry Society medal (2015)
Collaborations and grants: Lehtiö’s group secures major funding (e.g., Vinnova grants) and collaborates globally. They also organize doctoral courses like Proteomics by Mass Spectrometry and Omics Data Analysis.
